SOURCE: Healtheuniverse, Inc.

January 03, 2007 16:00 ET

Healtheuniverse Files PCT Patent Application With Coverage in 117 Countries for Method of Producing Collagen Producing Cells From Adult Stem Cells via Transfection

COVINA, CA -- (MARKET WIRE) -- January 3, 2007 -- Healtheuniverse Inc. (PINKSHEETS: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products, announced today that it has filed a patent application through the Patent Cooperation Treaty or PCT which is an international agreement for filing patent applications having effect in up to 117 countries. This application now protects the worldwide rights for the Company's method for producing collagen producing cells from adult stem cells via transfection. This proprietary technology marks the next step toward the Company becoming the first to commercialize non-embryonic stem cell use in the $15 billion worldwide plastic surgery and cosmetic surgery market.

The Company intends to sell its proprietary technology through packaged products and licensing agreements, once human clinical trials are completed, to plastic and cosmetic surgeons as a simple way for the industry to utilize our proprietary technology worldwide. The market for plastic, reconstructive, and cosmetic surgery procedures today exceeds $15 billion per year. It's estimated that cosmetic surgery procedures represent approximately $10 billion of industry revenues. Plastic Surgery encompasses both reconstructive and aesthetic surgery, commonly referred to as cosmetic surgery.

"Engineered fat tissue from stem cells is the ideal solution for patients with wrinkles, contour irregularities, and for breast augmentation," stated Dr. Vipul Dev, MD Chief Executive Officer of Healtheuniverse, Inc. "By utilizing adult stem cells via Healtheuniverse's packaged product, we hope to effectively engineer fat tissue and provide worldwide access to the technology for a variety of commercial surgical and cosmetic applications."


HEALTHeUNIVERSE Inc. is a biotechnology development firm specializing in the development and commercialization of patented Biopharmaceutical and Biomedical products. We are engaged in research and development of regenerative medicine therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications. More information on Healtheuniverse is available online at

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information

  • For more information, please contact:
    Healtheuniverse, Inc.
    Investor Relations
    Email Contact